Q1 2025 Protalix Biotherapeutics Inc Earnings Call Transcript

May 9, 2025 / 12:30 PM GMT

Release Date Price: $1.72 (-40.48%)

Transcript 10-Q8-K

Key Points

Positve

Protalix BioTherapeutics Inc (PLX) reported a significant increase in revenues from selling goods, reaching $10 million, a 170% increase compared to the previous year.
The company is progressing with the clinical development of PRX 115, with plans to initiate a phase two clinical trial for gout later this year.
Protalix BioTherapeutics Inc (PLX) is evaluating additional pipeline candidates, including PRX 119, which shows potential for further development.
The company has a strong partnership with PSE Global Rural Diseases, which is actively investing in medical and commercial programs.
Protalix BioTherapeutics Inc (PLX) has a solid financial position with cash, cash equivalents, and short-term bank deposits totaling approximately $34.7 million.

Negative

The cost of goods sold increased significantly by 215% to $8.2 million, primarily due to increased sales to Pfizer and Cruz in Brazil.
Research and development expenses rose by 21% to $3.5 million, driven by advancements in the clinical pipeline.
The company expects minimal revenues from license and R&D services going forward, aside from potential regulatory milestone payments.
There is uncertainty regarding the approval of the dosing frequency change for El Faulo by the European Medicine Agency.
Protalix BioTherapeutics Inc (PLX) faces potential competition in the gout treatment market, which could impact the success of PRX 115.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PLX.A - Protalix Biotherapeutics Inc
Q1 2025 Protalix Biotherapeutics Inc Earnings Call
May 09, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to the Protalex Biotherapeutics first quarter 2025 Financial and business results conference call. As a reminder, this conference is being recorded. I will now turn the conference over to our host Mike Moyer of Lifei Advisors, investor relations for Potalex.

Thank you. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and welcome to the Potalex Biotherapeutics first quarter 2025 Financial Results and Business Update conference call. With me today are Bon, President and CEO of

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.